Review Article

Alpha synuclein in hematopoiesis and immunity

Yu Pei [a], Robert W. Maitta [a,b,*]

[a] *University Hospitals Cleveland Medical Center, Cleveland, OH, United States*
[b] *Case Western Reserve University School of Medicine, Cleveland, OH, United States*

ARTICLE INFO

ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative condition and intracellular deposition of Lewy bodies in the substantia nigra (SN), which can cause dopaminergic neuronal death, is the hallmark of this syndrome. α-synuclein (syn) is a small protein expressed mainly in neurons but can also be found in a number of tissues. It can be present as a soluble monomer under normal physiological conditions, but can be toxic in its oligomeric or fibrillary forms. Most of the available literature has focused on the effects of α-syn pathology in the mechanisms leading to PD. However, the normal functions of α-syn still remain to be fully elucidated. Notably, α-syn in the hematopoietic system seems to mediate important functions as indicated by anemia and incomplete cell maturation when this protein is absent. This review will summarize basic genetic and structural findings, and critical information that suggests an essential role of α-syn in the development and activation of the hematopoietic system and immunity.

1. Introduction

1.1. Genetic, biochemical and structural characteristics of α-syn

Alpha synuclein (α-syn) is a small protein consisting of 140 amino acid residues that is a major component of Lewy bodies present in PD [1, 2], and is found to accumulate in presynaptic terminals of dopaminergic neurons of the substantia nigra (SN). Since α-syn was first identified in the brain, most of its basic properties including structure, genetic mutations, pathological features, and functions have been described in the central nervous system (CNS). To begin this review, basic CNS properties of α-syn will be summarized.

α-syn belongs to the synuclein family, which also has two other members, β- and γ-syn [2]. Each member of the family has unique tissue distribution and functions in the body. α-syn is mostly concentrated in the brain but it is also ubiquitously expressed in small concentrations in a variety of tissues including heart, lung, kidney, skeletal muscle [3, 4], Interestingly, it is well expressed and abundant in cells of the hematopoietic system [5]. Unlike α-syn, β-syn is mostly found in the brain, while γ-syn has been reported in a variety of neoplastic tissues, especially in invasive breast cancer and some types of sarcomas, and has been suggested as a potential prognostic biomarker in theses settings [6]. Studies have shown that there appears to be some functional redundancy among

the three synucleins since α-syn knockout ($^{-/-}$) mice are viable and only show minor neurological deficits [7]. Synucleins have also been shown to interact with each other so that β-syn has been reported to inhibit α-syn aggregation, and this provides neurons protection from pathological changes [8].

α-syn is encoded by the *SNCA* gene, and mutations and multiplications of the wild type gene are linked to the familial form of PD. Thus far, there are five *SNCA* mutations that have been described, including A30P, E46K, H50Q, G51D, and A53T [9, 10, 11, 12]. Each of these mutations leads to a different phenotype so that A53T, E46K, and H50Q promote higher rates of α-syn aggregation, while A30P has a slower fibrillary formation rate. Interestingly, G51D decreases α-syn aggregation rates, has a much earlier disease onset and patients with this mutation have α-syn inclusions in brain oligodendrocytes, a unique feature among α-syn mutations [12]. Additionally, each mutated form of α-syn shows different membrane affinity, and this binding affinity affects their potential to aggregate [13].

Structurally, α-syn is divided into 3 domains. The N-terminal domain contains 11-mer KTKEGV sequence repeats that are highly conserved among all 3 synucleins and across mammals. This domain forms apolipoprotein-like class A2 helical structures and is involved in membrane interaction and vesicle trafficking, especially in membranes with acidic phospholipid head groups [14]. Importantly, all of the afore-

---

mentioned α-syn mutations are found in this domain. The NAC (non-amyloid-beta-component) middle domain is hydrophobic and may be important in synucleinopathies [14]. The C-terminus is acidic, and has been shown to prevent aggregation and be protective in PD. This terminus is the target of post-translational modifications, and has been shown to bind Ca^{2+} and soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes. Additionally, the C-terminus has chaperone activity [15] and protects against oxidative stress [16].

α-syn has been described as an intrinsically-disordered protein due to its lack of an organized secondary structure [17]. Something that sets this molecule apart is that it can change its structure based on the surrounding microenvironment, and each conformation has characteristics lending to distinct functions. Under normal conditions, α-syn has been shown to be a soluble monomeric protein [18]; however, a helically folded α-syn tetramer has recently been identified in peripheral red blood cells (RBCs) [19] which has been suggested as the normal physiological form. This tetramer has greater lipid binding capacity than the monomeric form and is more resistant to aggregation. However, current research fails to fully explain the need for the tetramer to destabilize before changing into either oligomeric or fibrillary forms and more work is needed to resolve this mechanism. When the N-terminus of the protein interacts with lipid membranes [20] or high curvature ones [21], it changes to an α-helical conformation that allows it to interact and modulate synaptic vesicles. Oligomeric forms, different from the tetrameric form, have been observed prior to fibril formation of varying sizes and morphology [22], and appear to represent the most toxic forms of α-syn [23]. Of interest, the amyloid-like fibrillary aggregated α-syn is found in Lewy bodies that accumulate in dopaminergic neurons potentially resulting in cell death. α-syn forms different fibrillary structures in the presence or absence of bacterial endotoxin lipopolysaccharide (LPS). α-syn interacts with LPS via its N terminus and in turn different fibrillary conformations show unique interactions with microglia [24]. Interactions such as these with bacterial membranes may hint at potential mechanisms that explain the observed antimicrobial properties of α-syn [25]. Further research will be needed to solve these questions.

Since α-syn lacks signaling sequences needed to be transported extracellularly, it is usually identified as cytoplasmic protein yet also closely associated to membranes. Recently, α-syn has been identified in the nucleus of human cell lines and mouse neurons where it is thought to be involved in DNA repair [26]. Outside cells α-syn has been found in plasma and cerebrospinal fluid (CSF) of both PD patients and healthy controls [27, 28]. α-syn in CSF may result from neuronal secretion, either by degenerating neurons under stress due to the disease state [29] or by normal neurons [28, 30]. On the other hand, the origin of α-syn in plasma is less clear since peripheral blood mononuclear cells (PBMCs), RBCs, and platelets express α-syn in increasing concentrations from low to highest. Notably, increased concentrations of plasma α-syn are observed in PD patients secondary to neuronal degeneration that increases its concentration in CSF with subsequent efflux into plasma [29]. Interestingly, release of α-syn into plasma can also occur in a time-dependent manner secondary to aging of platelets as recently described in single donor platelet units during storage making it also a potential biomarker for studying biochemical changes during platelet storage [31].

Study of neurons has allowed for several mechanisms of α-syn secretion to be proposed. Unconventional exocytosis is one of these mechanisms [30]. In neuroblastoma cell lines overexpressing human α-syn, the protein selectively entered cytosolic vesicles and was secreted independently of the endoplasmic reticulum (ER)-Golgi classical vesicular pathway. This vesicular α-syn is more aggregation-prone compared to the cytosolic form and alternatively it can be secreted via exosomes [32, 33]. It has been shown that after radioactive α-syn injection into mice brains, their plasma contained radioactive α-syn in CNS-derived exosomes [32]. These α-syn-containing exosomes have been found in both PD patients and healthy controls. This exosomal pathway was also seen in human neuroblastoma cell lines expressing wild type α-syn and appeared to be modulated by cytosolic Ca^{2+} concentration [33]. However, presence of free soluble α-syn suggests that exosomal secretion is just one of the mechanisms of α-syn secretion. α-syn-containing erythrocyte-derived extracellular vesicles (EEVs) can be another potential source of the protein found in plasma. These EEVs have been identified in plasma of both PD patients and healthy controls [34]. Notably, EEVs have been shown to cross the blood brain barrier (BBB) via adsorptive-mediated transcytosis during LPS-induced peripheral inflammation where they co-localize with microglia [35]. In addition to neuro-inflammation, microglia can also uptake plasma-derived α-syn containing exosomes and transmit them to neurons resulting in neuronal toxicity [36]. Finally, degradation of extracellular α-syn by proteases could provide another mechanism by which neuronal toxicity and neuro-inflammation occur once these protein fragments are uptaken by either neighboring cells or microglia [37].

Nevertheless, despite a greater understanding of this protein's conformational variants, pathological mechanisms leading to PD remain unclear especially if disease results from a gain of toxicity by α-syn aggregation or if it is secondary to loss of normal function. However, due to the bidirectional transport of α-syn across BBB, changes to protein structure/function in the periphery secondary to the distinct biochemical properties of blood and its cells or through interaction with pathogens could therefore affect CNS cells [38]. *In vivo* models expressing known α-syn mutations, overexpressing wild-type protein, and α-syn$^{-/-}$ mice have shed light into its potential functions. At the cellular level, α-syn-protein interactions have been elucidated in yeast, Drosophila, and megakaryocytic/erythroid cell lines. Of these, at least in Drosophila α-syn expression is temporally and spatially regulated through development [5]. The functions for α-syn so far identified from these models include reduction of oxidative stress, regulation of neurotransmitter release, and modulation of SNARE protein complex assembly [39].

1.2. α-syn in microglia

In order to understand the potential functions that this protein has in the hematopoietic system it is worth to look at studies describing a cell population that resembles those in this system, i.e. the microglia. Even though these cells are not bone marrow-derived they share immunological properties with peripheral monocytes and macrophages. It is these similarities which make microglia studies important to understanding data presented later in this review relevant to hematopoiesis and immunity.

Microglia are constantly sensing the CNS microenvironment and once activated they can differentiate into either a classical M1 or an alternative M2 phenotype. Classical M1 microglia produce pro-inflammatory cytokines and promote T helper (h)1 $CD4^+$ T cell activation, while activation of M2 microglia results in enhanced anti-inflammatory and tissue repair responses [40, 41]. α-syn modulates both microglia phenotypes and subsequent activation in response to stimuli.

Changes to microglia have been reported in PD patients including cell morphology, surface protein expression, antigen presentation, and phagocytosis [42]. Experimentally, α-syn can be overexpressed by microglia, exogenously assembled and added to microglia cell cultures, expressed on neighboring neurons, or secreted into culture media by dying neurons. In addition, the concentration and conformation of α-syn influence microglia phenotype. Murine-derived microglia cell lines transfected with human wild type, mutant A30P, and A53T α-syn forms showed increased levels of cyclooxygenase (Cox)-2, secretion of pro-inflammatory cytokine tumor necrosis factor (TNF)-α, interleukin (IL)-6, and nitric oxide production in the setting of impaired phagocytic function [43]. Moreover, microglia from transgenic mice overexpressing α-syn have shown decreased phagocytosis and cytokine release [44]. In particular, neuronal overexpression of α-syn led to increased microglia activation in mice. In this model, microglia were activated by α-syn from

SN neurons resulting in altered cell morphology including increased cytoplasm, swelling of cellular processes, and pro-inflammatory responses mediated by higher expression of intercellular adhesion molecule-1, IL-1α, IL-6 and TNF-α in a time dependent manner [45]. Separately, it was shown that diffuse neuronal overexpression of wild type human α-syn leads to microglia activation in a temporally- and regionally-specific manner through increased expression of toll-like receptors (TLRs)-1, -4, and -8 restricted to the cerebrum's striatum and SN but not in the cerebral cortex or cerebellum [46]. Experimentally, viral vectors that lead to expression of different doses of human α-syn in rat brain can mimic both early and late PD stages. In the early stage, with limited neuronal α-syn fibrillary accumulation, microglia show responses characterized by higher major histocompatibility complex (MHC) II expression (higher antigen presentation), whereas in late stage when α-syn-induced neuronal pathology and cell death occur, microglia demonstrated slower responses with increased phagocytic maker CD68 expression and adaptive immune system infiltration [47]. In α-syn$^{-/-}$ mice microglia showed a ramified vacuolar morphology, increased reactive marker expression, high pro-inflammatory cytokine production after LPS stimulation, and decreased phagocytosis [48]. Likewise, altered expression of key enzymes in lipid-mediated signaling pathways including cytosolic phospholipase, Cox-2, and phospholipase D2, which are essential to microglial cytokine secretion and phagocytosis, occur in microglia isolated from α-syn$^{-/-}$ mice. This provides one plausible explanation for the altered microglia phenotype in these mice [49].

Receptors expressed on microglia appear partly regulated by α-syn. Among their functions are sensing the microenvironment, ligand recognition, and initiating downstream signaling pathways in response to pathogens or cell damage [50]. α-syn plays a role in the function of TLRs, scavenger receptors, complement receptors, Fc receptors and NADPH oxidase (NOX) activity among others. TLRs belong to the family of pattern-recognition receptors (PRRs) critical to innate immunity, triggering NF-κB activation or interferon regulatory factor-3 signaling pathways after ligand binding [51]. α-syn functions as a danger/damage-associated molecular pattern molecule recognized by TLRs and thus modulates microglia function. For example, α-syn released from neuroblastoma cells activates murine primary microglia in culture through α-syn-TLR-2 interaction leading to cell proliferation and cytokine production [52]. Similarly, extracellular α-syn released from human neuroblastoma cells overexpressing it acts as an endogenous agonist of TLR-2 activation in a conformation-dependent manner. TLR-2 binds and internalizes α-syn leading to early activation of pro-inflammatory pathways [53]. As a stimulating agent, α-syn also appears to have profound effects even at low protein concentrations of its oligomeric form capable of sensitizing microglia *in vitro* and activating pro-inflammatory cascades through TLR-4-dependent signaling [54]. Altered TLR expression in response to α-syn has also been reported, as shown by increased expression of TLR-1, -2, -4, and -8 that mediate the temporally- and regionally-specific activation of microglia in a mouse neuronal model overexpressing human α-syn [46]. In addition, when murine microglia cell lines are treated with mixtures of recombinant human monomeric, oligomeric, and fibrillary forms of α-syn, changes to TLR expression are observed such as upregulation of TLR-2, TLR-3, and downregulation of TLR-7 [55].

Scavenger receptors expressed on microglia recognize modified lipoprotein and various polyanionic ligands, one of which is CD36 [50], that has been shown to mediate *in vitro* microglia activation by exogenous human α-syn [56]. This receptor, can be used by α-syn to enter microglia, prime the cell, and lead to inflammasome assembly [57]. Of note, higher CD36 mRNA expression in activated microglia has been reported in transgenic mice overexpressing double mutant α-syn A53T and A30P. Furthermore, microglia from CD36$^{-/-}$ mice showed partially attenuated cell activation after treatment with exogenous double mutant human α-syn suggesting that activation is partially mediated by CD36 and its signaling pathway [58], and that likely additional receptors facilitate activation [56].

Macrophage antigen complex (MAC)-1 is a complement receptor consisting of CD11b (integrin α$_M$) and CD18 (integrin β$_2$) that functions as both adhesion molecule and PRR [50]. In mesencephalic cultures, both wild type and mutant forms of α-syn have to bind to and signal through MAC-1 receptors to activate microglia to produce reactive oxygen species (ROS), and mutant forms have shown enhanced neurotoxicity possibly via a MAC-1-dependent mechanism [59]. However, α-syn can also function as a chemo-attractant to direct microglia migration [60]. Specifically, binding of extracellular aggregated α-syn to CD11b on microglia is necessary for microglia directional migration mediated by H$_2$O$_2$ produced from activated NOX [60]. In addition, α-syn has been shown to interact with another integrin family receptor β-1 (CD29) that results in modulation of microglia migration and morphological changes [52].

Fcγ receptor (FcγR) proteins expressed on the surface of microglia bind IgG among other ligands. FcγR activation triggers downstream immunoreceptor tyrosine-based activation motif signaling pathways that result in sequential activation of Src and Syk kinases followed by activation of MAPK and NF-κB [51]. α-syn activates microglia NF-κB signaling and downstream pro-inflammatory mediator production via its interaction with FcγR. Along these lines, FcγR can mediate α-syn internalization and traffic to the autophagosome; and diffuse α-syn cellular localization and impaired NF-κB activation have been reported in microglia of FcγR$^{-/-}$ mice [61]. Likewise, selective overexpression of α-syn in SN results in activation of NF-κB that is FcγR expression-dependent [62].

NOX on the microglia membrane generates ROS which are important to host defense and redox signaling [63]. NOX can be activated by microglia receptors PRRs and MAC-1 in response to stimuli, one of which is α-syn. After phagocytosis by microglia, extracellular aggregated human α-syn activates NOX increasing ROS production [64]. Furthermore, α-syn directs microglia migration via the NOX pathway [60]. Another receptor critical to microglia function that is regulated by α-syn is MHC-II. In mice, overexpression of human α-syn in SN resulted in increased MHC-II expression on activated microglia; while *in vitro* microglia showed increased antigen processing and presentation after treatment with aggregated α-syn [65].

α-syn, therefore, mediates the interaction between CNS and the periphery by modulating microglia function. Overexpression of human α-syn in mouse SN led to infiltrating B cells, T cells, and microglia activation in this region 4 weeks after viral vector injection; on the other hand by the 12th week while activated microglia declined, T and B cells infiltration persisted [45]. Late increases in CD4$^+$ and CD8$^+$ T cells have also been observed in the periphery after induced overexpression of human wild type α-syn in mouse brain [46]. It has also been shown in a similar mouse model that infiltrating T cells induced microglia and resident macrophages to differentiate into the M1 phenotype; while in the absence of lymphocytes, increased macrophage infiltration, decreased α-syn aggregation, and highly phagocytic microglia with the M2 phenotype were observed [66].

To summarize, microglia studies provide a foundation to understand the potential functions that α-syn may have in immune cells and in the hematopoietic system. Likewise, even though monocytes and macrophages reside in a different microenvironment from microglia they have similar protein receptors, signaling pathways, and interactions with T and B cells which suggest that the potential functions and/or mechanisms α-syn has in the hematopoietic system may resemble those described up to this point in the CNS.

2. Main text

2.1. α-syn in the hematopoietic system

Expression of α-syn in erythrocytes, T and B lymphocytes, monocytes, natural killer (NK) cells, and megakaryocytes has been known for quite some time [5], and this expression extends to hematopoietic neoplastic cells [67]. High α-syn expression under normal conditions and

dysfunctional hematopoietic cells in α-syn$^{-/-}$ mouse models suggest that this protein plays an important role in maturation and normal function of this system [68, 69, 70]. More importantly, hematopoietic abnormalities have been reported in PD patients [71], suggesting that an association between α-syn expression/conformation and hematopoietic function exists. Therefore, the remainder of this review will present data in the context of this system.

PBMCs which include B lymphocytes, T lymphocytes, NK cells, and monocytes are essential to competent immunity. For almost twenty years it has been known that α-syn is expressed in PBMCs [5]; however, despite this knowledge there is no clear indication of those functions that α-syn mediates in these cells. PD patients show cell changes that include: quantitatively altered immune cell subpopulation distribution, modifications to cell morphology and function, and altered expression of both MHC-I and MHC-II molecules. This is further supported by recent findings describing that leukocytes from α-syn$^{-/-}$ mice have abnormal ultrastructural morphology [72]. Since expression of α-syn is increased in PBMCs of PD patients, α-syn could affect and therefore be important functionally in these cells. One of these functions is sensitivity of PBMCs to apoptosis since overexpression of wild type α-syn as well as expression of its mutant forms induce PBMC apoptosis [73]. α-syn gene changes have also been identified in PBMCs of PD patients [74]. Among these, hypomethylation of CpG-2 sites may be associated with increased α-syn expression in leukocytes of PD patients. α-syn overexpression activates the JAK/STAT pathways promoting dysregulation of innate and adaptive immunity. This overexpression upregulates SN genes which are

important in adaptive immunity including antigen presentation, Ca^{2+}-induced T lymphocyte apoptosis, B cell development, and graft-vs.-host disease [75]. Potentially, changes reported in PD patients' PBMCs could result from a loss of normal α-syn function, or PBMCs respond to it as foreign triggering an immune response. We will now discuss each cell type expressing α-syn separately.

2.1.1. α-syn in T cells

T cells depend on their cell surface protein expression and corresponding function to differentiate into either CD4$^+$ helper T cells or CD8$^+$ cytotoxic T cells. CD4$^+$ T cells are further subdivided into regulatory T cells (Treg) [76] and effector T cells (Teff). Treg cells are CD4$^+$CD25$^+$FOXP3$^+$ and mediate immune tolerance and suppression. On the other hand, Teff cells can be further divided into Th1, Th2, and Th17 subgroups based on their cytokine production profiles [77]. Th1 cells produce interferon-γ (IFN-γ) and mediate intracellular pathogen clearance; while Th2 cells produce IL-4, IL-5, and IL-13, mediate T helper function in humoral immunity, clearance of extracellular pathogens, and allergic responses. Th17 produces IL-17, mediate tissue inflammation and potentially autoimmunity [77]. Importantly, changes in T cells as well as changes in α-syn have been reported in PD patients. α-syn could be recognized as an intracellular or extracellular antigen, that depending on its origin and conformation, trigger immune responses exacerbated by different T cell subsets. Alternatively, changes in T cells could result from loss of normal α-syn function leading to defective or dysregulated T cell maturation and/or function (Fig. 1).


Fig. 1. Diagram of a generic white blood cell outlining some of the pathways that may be mediated or regulated by α-syn. Representation describes interaction with SNAREs in different cell types, receptors regulated or affected by α-syn expression and those cell processes that depend on regulated α-syn expression. BCR: B cell receptor, TCR: T cell receptor.

Studies have shown that in PD patients the percentage of T lymphocytes is decreased [78], there is a decreased CD4$^+$/CD8$^+$ ratio [79], fewer naïve helper CD4$^+$CD45RA$^+$ T cells [80], a shift toward Th1 cells [78, 79, 81] and Th17 cells [81], decreased percentage of Treg cells and Th2 cells [79, 81], and a selective increase in proportion of CD4$^+$CD45RO$^+$ memory T cells [82, 83]. These T cell subset changes suggest the presence of a chronic induction signal in PD stimulating T cell activation [83]. Furthermore, conflicting reports of either decreased percentage of Th1 cells [84] or increased number of activated CD4$^+$CD25$^+$ T cells [85] could be the result of analysis of different cell markers and/or inclusion of patients with different disease states.

Recent data using α-syn$^{-/-}$ mice indicates that deficiency of this protein leads to arrest in T lymphocyte maturation including Treg cells [69], as well as abnormal T cell distribution in lymphoid organs including thymus, spleen and lymph nodes. In this model, the total number of thymocytes was reduced with significant decreases in both CD4$^+$ and CD8$^+$ cells and increases in the number of double negative thymocytes. Morphologically, thymi from these mice were smaller with a relatively large cortex and small medulla. T cell subset analysis indicated defective Th2 differentiation and a shift toward Th1 phenotype (as mentioned earlier in PD patients) after *in vitro* activation. Percentage of Treg was decreased in the thymus but increased in the spleen. Functionally, there was hyperactivity of remaining mature T cells in a background of altered cytokine production profile [69]. Notably, such T cell subset distribution abnormalities have also been described in an α-syn$^{-/-}$ multiple sclerosis mouse model. These mice had early onset of autoimmune encephalomyelitis, increased frequency of Th1 cells and decreased frequency of Tregs in the spinal cord, and higher frequency of Th1 cells in the spleen. Taken together, these findings suggest that α-syn functions as a Th1 response regulator [86].

Vectors that increase α-syn expression change T cells subset composition. Mice subcutaneously immunized with α-syn 6 weeks and 10 weeks before overexpression of human α-syn in SN show microglia activation with upregulation of MHC-II expression, increase in Treg and B cell infiltration, and high titer of C-terminal-α-syn-specific IgG antibodies [87]. Additionally, mice injected with low dose α-syn on day 0 and day7, and sacrificed on day 14, showed an increased percentage of Treg and reduced percentage of Teff in the spleen [88]. Post-transcriptional modifications of α-syn may modulate T cell function. T cells harvested from a mouse model immunized with nitrated-α-syn polarized to a Th1 and/or Th17 phenotype showed Treg with impaired inhibitory capacity [89]. Immunization with different conformations of α-syn also modulated peripheral T cells subset distribution in murine models. In this setting, monomeric α-syn reduced the percentage of CD4$^+$ T cells, nitrated α-syn increased total number of T cells, and fibrillary α-syn increased the percentage of Treg. [90] These data indicate that α-syn is important to T cell development, response to stimulus and function, cell distribution, and cytokine production.

2.1.1.1. α-syn and SNARE protein complexes in T cells. The function of a protein is highly dependent on its structure. Because of the sequence and chemical properties of each functional domain, α-syn is able to interact with membranes and modulate synaptic vesicles through direct or indirect interactions with SNARE proteins. These proteins contain a conserved 60 - 70-amino acid domain called the SNARE motif. They are classified into vesicle-membrane SNAREs (v-SNAREs) and target-membrane SNAREs (t-SNAREs) based on cellular location and function. They can also be divided into Q-SNAREs and R-SNAREs based on structure. Q-SNAREs are subdivided into Qa-, Qb-, Qc-, and potentially Qb,c-SNAREs based on the amino acid sequence of the SNARE motif [91]. Formation of the SNARE protein complex, which is a tetrameric coiled-coil structure between appropriate set of v-and t-SNAREs, brings opposing membranes into close proximity to facilitate fusion [92]. SNARE proteins are critical in vesicular transport and have been shown to be important in neuronal synapses. SNARE proteins described in the CNS include synaptic proteins syntaxin-1, synaptosomal nerve-associated protein (SNAP)-25, and vesicle-associated membrane protein (VAMP)2 (or synaptobrevin 2). Syntaxin-1 is a type 1 integral membrane protein found on the plasma membrane. SNAP-25 attaches to target membranes via its central region, leaving its amino- and carboxyl-termini to interact with syntaxin-1 and VAMP2 (associated with vesicle membranes). These proteins then coalesce to form a four-helix SNARE complex with one SNARE motif from each syntaxin-1and VAMP2, and two motifs from SNAP-25 [93]. After docking and priming neurotransmitter-containing vesicles in the active zone [94], v- and t-SNAREs pull the membranes closer together leading to fusion and neurotransmitter release.

Pathological models expressing multiple copies of wild-type or mutant forms of α-syn have shown inhibition of SNARE protein function. Current evidence has identified α-syn as a protein chaperone that facilitates SNARE protein assembly. This function was identified in a murine model lacking cysteine-string protein-α (CSPα), a presynaptic protein chaperone important for complex assembly. In CSPα deficient mice, there is decreased SNAP-25, and chaperones Hsc 70 and Hsp 70 leading to impaired SNARE complex formation. Transgenic expression of human and murine wild type, as well as A53T mutant human α-syn partially compensate for loss of CSPα and rescue complex assembly [95]. Wild-type α-syn has been shown *in vitro* to promote SNARE protein complex assembly by clustering vesicles at the active zone, thus preventing loss of accessory proteins and increase in assembly rates. To achieve this, α-syn binds to both VAMP2 and anionic lipids [96]. For example, cytosolic monomeric α-syn changes to a multimer when binding to the membrane and VAMP2 which results in clustering and local increase of VAMP2 concentration [97]. α-syn can also directly promote complex assembly in a dose-dependent manner. Not surprisingly, in αβγ-triple KO mice, there is an age-dependent decrease in SNARE-complex assembly that is reversed with reintroduction of α-syn. In this model the C terminus of α-syn binds to VAMP2 while the N terminus binds to phospholipids [98]. α-syn also indirectly inhibits complex assembly by blocking arachidonic acid, a common lipid regulator released from membranes that promotes SNARE complex formation and exocytosis [99].

Notably, both regulatory and toxic effects of α-syn over SNARE proteins depend upon its concentration and conformation. High concentrations of non-aggregated α-syn inhibits vesicle docking by binding to negatively charged lipids without direct SNARE protein interaction [100]. Importantly, mutated forms of α-syn with higher lipid binding affinity have higher inhibitory potential [100]. On the other hand, large α-syn oligomers inhibit vesicle docking at lower concentrations that require direct binding to the N terminus of VAMP2 [101]. Therefore, both α-syn concentration and conformation must be maintained in a delicate balance to preserve normal function.

Analogous to the active zone in the neuronal synapse, the immunological synapse consists of a protein network formed at the cell surface in the area of contact between the T cell and antigen-presenting cell (APC) [102]. This synapse consists of three rings of membrane receptors, cytoskeletal elements, and signaling proteins. The first of these rings, the central supramolecular activation cluster (cSMAC) is made of the T cell receptor (TCR) and signaling molecules, the second or peripheral SMAC (pSMAC) consists of a ring of adhesion molecules, and the third (distal) ring dSMAC consists of membrane proteins such as CD45 [103]. This arrangement is analogous to protein complexes in neurons which express them in the presynaptic terminal while in T cells complexes occur anywhere on the cell surface [104]. SNARE protein-mediated vesicle trafficking is critical in both mechanisms. These proteins are ubiquitously expressed in T cells [102, 104], and are critical to cell maturation and function at the immunological synapse such as delivery of cell surface receptors or signaling molecules, and secretion of lytic granules and cytokines.

SNARE proteins modulate T cell maturation in the thymus. During T cell development, cells go through positive and/or negative selection in the thymus. These T cell developmental stages are tightly regulated by

the expression of distinct stage-specific cell surface molecules, and interaction between thymocytes and APCs such as thymic epithelial cells and dendritic cells that determines the fate of thymocytes [105]. This complex process is intimately modulated by SNARE proteins [106]. Among these, VAMP8 controls the organization of the thymic epithelium, thereby regulating thymocyte proliferation and apoptosis in thymic stroma. Along these lines, VAMP8-deficient mice have a smaller thymus with a disorganized thymic epithelium, and a decreased total number of thymocytes with double positive thymocytes most severely affected. This is similar to the phenotype seen in α-syn$^{-/-}$ mice [69]. Likewise, reduced proliferative and increased apoptotic thymocytes have also been demonstrated.

SNARE proteins are important to T cell activation. Mechanistically, the TCR interaction with peptide antigens presented by MHC on APCs triggers downstream signaling pathways [107]. For this to work, delivery of the TCR and signaling molecules to the immunological synapse is essential to drive T cell activation [108]. Specifically, SNARE proteins assist polarized recycling of TCR at the immunological synapse via recycling endosomes [109]. t-SNARE proteins such as syntaxin-4 and SNAP-23 are necessary for TCR accumulation at the synapse. Notably, inactivation of v-SNARE proteins by tetanus toxoid inhibited TCR accumulation, and of these VAMP2 and VAMP3 may contribute to this polarized recycling process [109]. On the other hand, in cytotoxic T lymphocytes, syntaxin-7 mediates accumulation of recycled TCRs at the synapse. Reports indicated that syntaxin-7 deficiency blocked polarized recycling of TCRs from early to late endosomes leading to inefficient accumulation of TCRs and lytic granules at the synapse [110]. SNARE proteins also mediate the delivery of signaling molecules to the immunological synapse. Two of these molecules, lymphocyte-specific-protein tyrosine kinase and linker-for-activation of T cells are critical to T cell signaling and activation. Each has a unique vesicular compartment made of different Rab GTPases and SNARE proteins which temporally and spatially regulate signaling [111].

SNARE proteins also modulate Teff response. Th cells secrete cytokines that modulate immunological responses and two cytokine export pathways are essential in these cells. In one IL-2 and IFN-γ are secreted directly into the synapse while in the other TNF-α can be multidirectional. Both processes involve SNARE proteins such that syntaxin-6 co-localizes only with TNF-α and shows little localization with IL-2 and IFN-γ, while vesicle transport through interaction with t-SNAREs homolog 1b (Vti1b) partially overlaps with both types of cytokines. This provided evidence that SNARE proteins mediate cytokine secretion from Th cells, that certain SNARE proteins are pathway-specific, while others are shared by pathways [112].

Cytotoxic T cells recognize and destroy intracellular pathogens. One of the mechanisms used by these T cells is release of lytic granules at the synapse [113], and SNARE proteins mediate this release. For example, in the mouse model, VAMP2 is the v-SNARE controlling the final fusion step in cytotoxic T cell granule release [114]. Likewise, VAMP8 is expressed on lytic granules and cells lacking VAMP8 show normal granule polarization to the synapse but defective target cell killing. Importantly, this partial deficit observed in VAMP8 deficient mice indicates that additional v-SNARE proteins, possibly VAMP7, also mediate granule release [115]. Additionally, based on structural characteristics and previous studies, syntaxin-11 and SNAP-23 are predicted to be the t-SNARE proteins mediating the fusion step of lytic granule release [116]. This appears to be the case since VAMP7, syntaxin-11, and SNAP-23 have been identified in human cytotoxic T cells as facilitators of lytic granule exocytosis [117].

To maintain normal T cell maturation and function it is important to keep T cells and APCs in close proximity, to efficiently recycle and relocalize cell surface receptors and accessory proteins to the synapse, and to effectively produce and secrete mediators such as perforin and cytokines to execute immune functions. SNARE proteins are critical modulators of these processes. Therefore, interactions between SNARE proteins and α-syn could modulate T cells function and potentially affect hematopoiesis across lineages. This hypothesis could explain the altered

T cell phenotype observed in PD patients and α-syn$^{-/-}$ mice. It would also explain how absence of α-syn changes leukocyte cell size, shape of secretory particles, increases smooth endoplasmic reticulum, number of secretory granules, and inclusion bodies [72]. This phenotype could result from defective SNARE protein complex assembly linking α-syn to leukocyte vesicular trafficking.

2.1.1.2. α-syn in T cell apoptosis. α-syn may modulate T cell apoptosis since changes to apoptosis receptor expression have been described in PD [80]. CD95 is an apoptosis signal receptor encoded by *FAS* gene [118] that is highly expressed in cytotoxic CD8$^+$ compared to CD4$^+$ cells of healthy subjects. In CD4$^+$ T cells, this receptor is mainly expressed on memory cells and activated CD4$^+$CD25$^+$. PD patients have increased percentage of CD95/Fas$^+$ CD4$^+$ cells, mainly naïve CD4$^+$CD45RA$^+$ T cells [80]. This increased CD95/Fas expression correlates with decreases in CD4$^+$ T cells and of absolute counts of CD4$^+$CD45RA$^+$ T cells. These CD95/Fas$^+$ naïve CD4$^+$ T cells may be more sensitive to apoptosis than memory CD4$^+$ T cells which are CD95^{high} even in healthy controls. Cellular alterations in T cells of PD patients involve sensitivity changes to apoptosis which are partly mediated by α-syn [80]. It should be of interest, that overexpression of α-syn and mutant forms of α-syn upregulate CD95 gene expression in hematopoietic cell lines [73].

2.1.1.3. α-syn in T cell autophagy. Authophagy is a cellular process of protein/organelle degradation in response to either cell starvation or abnormal protein accumulation [119]. PBMCs from PD patients have high concentrations of nitrotyrosine-modified α-syn as well as enhanced autophagy [120]. The enhanced phenotype may result from this post-translational modification since α-syn is a negative regulator of autophagy. To support this, knocking-down α-syn resulted in higher T cell autophagy [121]; and expression of autophagy-related proteins correlates with α-syn concentration in PBMCs of PD patients [122]. α-syn modifications can also be a consequence of altered autophagy, since inducing autophagy led to decreased monomeric and aggregated α-syn in T cells while impaired autophagy increased α-syn concentration [121].

2.1.1.4. α-syn and dopaminergic receptors on T cells. α-syn interacts with dopaminergic receptors (DRs) expressed on CD4$^+$ T cells to modulate their function. Five different dopaminergic receptors have been identified belonging to two distinct groups. D1 and D5 belong to the D1-like family and D2, D3, and D4 to the D2-like group. CD4$^+$ T cells express all five DRs showing inter-individual variability [123]. D1-like DRs expressed on naïve CD4$^+$CD45RA$^+$ T cells play a role in dendritic cell–induced naïve T cell stimulation that results in Th2 polarization [124]. On the other hand, D3 promotes T cell differentiating into Th1 phenotype [125]. DRs are also involved in cytokine release by T cells. D3 mediates release of TNF-α and D2 triggers secretion of IL-10 [126]. Interestingly, there is higher DR expression in apoptotic cells [123]. PD patients show different expression of DRs on CD4$^+$ T cells compared to healthy controls. These expression differences also vary among CD4$^+$ T cell subsets [127]. Both monomeric and fibrillary α-syn have been shown *in vitro* to alter expression of DRs on naïve and memory CD4$^+$ T cells. The monomeric form increases D5 and D2 expression on naïve T cells, and D2 on central memory T cells; on the other hand, fibrillary α-syn increases D1, D2, and D4 on central memory T cells, and D1, D4 on effector memory cells [127]. Separately, in mice DR expression on CD4$^+$ T cell subsets changed in response to immunization with different forms and concentrations of α-syn. Moreover, immunization with α-syn modulates expression of homing marker CCR6 and tolerance marker CD103, and a relationship between both markers and DRs DR2 and DR3 has been observed [90, 128]. Therefore, α-syn can modify T cell function and subset distribution by changing DR expression on T cells.

2.1.2. α-syn in B cells

B cells produce antibody through mechanisms that depend on the

type of eliciting antigen and requirement for T cell help [129]. α-syn is expressed in B cells and changes to B cells of PD patients have been described [82, 84]. Autopsies of brains from PD patients have shown IgG deposition but not IgM against α-syn, mainly IgG1 co-localized with α-syn to surfaces of cell membranes and Lewy bodies in neurons, and the proportion of IgG positive neurons negatively correlated with the degree of cell loss [130]. Autoantibodies have also been detected in peripheral blood of familial PD patients with specificities to multiple epitopes across human α-syn [131]. When human α-syn transgenic mice were vaccinated with human α-syn, antibodies were detected in serum recognizing the C-terminus of α-syn [132]. In theory, changes to B cell numbers and humoral responses in PD could result from loss of normal α-syn function or stimulation of autoantibody responses.

Abnormalities in B lymphocytes have also been reported in α-syn$^{-/-}$ mice [68]. This report indicated that absence of α-syn led to significant decreases in absolute B cell counts, specifically mature B lymphocytes in a background of smaller and disorganized lymphoid follicles, and decreased total serum IgG concentration without changes in IgM production indicative of defective immunoglobulin isotype class switching. Furthermore, IgG production was absent in response to challenges with both T-independent and T-dependent antigens. Taken together with findings reporting increases in the number of inclusions and secretory granules in PBMCs [72], it suggests that α-syn is essential to maturation and normal function of B cells (Fig. 1).

Similar to what we described for T cells, one potential mechanism by which α-syn regulates B cells is through interactions with SNARE protein complexes. After T cells and B cells come into contact at the synapse, which is regulated by SNARE proteins, a subgroup of B cells differentiates into plasma cells. These cells are critical to producing and secreting antibodies [129]. SNARE proteins regulate antibody secretion by plasma cells. All isoforms of VAMP family, except for VAMP1, have been identified in human plasma cells at different levels of expression. For example, VAMP2 is responsible for secretion of antibodies from plasma cells [133]. Likewise, SNAP-23 [134] and syntaxin-4 [135] have been identified as the corresponding t-SNARE proteins mediating antibody secretion.

Interaction with helper T cells, especially Th2, induces B cells to undergo clonal expansion, somatic hypermutation, immunoglobulin isotype class switching, and differentiation into memory B cells or plasma cells [136]. In α-syn deficiency, a defective immunological synapse could be caused by the inefficient delivery of receptors to the cell surface in both T cells and B cells or by impaired cytokine production by Th cells resulting in dysfunctional immunoglobulin class switching. This could partly explain the normal IgM concentration and low to absent of IgG production in α-syn$^{-/-}$ mice [68]. Alternatively, as indicated by the accumulation of secretory vesicles and inclusions in PBMCs of these mice, a defective secretory pathway in plasma cells could also be responsible for the observed phenotype [72].

α-syn may also modulate B cells through its interactions with DRs [137]. By using flow cytometry, it was shown higher expression of DRs D2, D3 and D5, and lack of D1 expression on B cells from healthy donors compared to other types of PBMCs. This is important since as discussed earlier α-syn closely interacts with DRs and mechanistically it can also exert regulation of B cell function through this interaction.

2.1.3. α-syn in NK cells

NK cells recognize down-regulation of self MHC-I molecules on virally-infected cells or tumor cells that trigger their cytotoxicity. NK cells release lytic granules and secrete cytokines at the immunological synapse to kill target cells [138]. Changes in the percentage of NK cells of PD patients have been observed. Likewise, when NK cells from PD patients were stimulated with human α-syn peptides, there was a higher percentage of NK cells producing TNF-α [139]. Since α-syn is also expressed in NK cells, it is feasible that it may regulate NK cell function through interaction with SNARE protein complexes (Fig. 1). Similar to cytotoxic T cells, target killing by NK cells is facilitated by SNARE proteins. NK cells

express all seven VAMP family members. Of these VAMP4 and VAMP7 co-localize to lytic granules in activated NK cells and both are essential to NK cell degranulation and cytotoxicity; however, VAMP7 may have broader regulation over NK cell functions [140]. On the other hand, t-SNARE protein syntaxin-11 is expressed and regulated in a cell-type specific manner in different NK cell lines. Notably, in resting NK cells syntaxin-11 is found in distinct vesicular compartments different from those containing Rab27a or perforin, while all three co-localize at the synapse in activated cells [141].

2.1.4. α-syn in monocytes and macrophages

Monocytes can differentiate into macrophages or dendritic cells [142]. Dysregulation of monocytes and macrophages occur in PD patients and a mouse model overexpressing α-syn [44] (Fig. 1). Interestingly, monocytes from sporadic PD patients and a patient carrying a triplication of the α-syn gene have shown higher α-syn expression and impaired phagocytosis [44]. Monocytes from PD patients have an altered transcriptome and cell subset composition characteristic of a pro-inflammatory phenotype. These cells also show hyper-activation post-LPS stimulation and impaired phagocytosis [143]. Overexpression of human α-syn in murine brain can drive pro-inflammatory peripheral monocyte migration to the CNS that requires expression of the chemokine receptor CCR2 on monocytes [144]. α-syn can also serve as an inflammatory mediator that activates monocytes *in vitro*. When human monocyte cell lines were incubated with a combination of α-syn and IFN-γ, they produced pro-inflammatory cytokines IL-1β and TNF-α via receptor-mediated activation of MAP kinase signaling pathways [145]. In this regard, both monomeric and fibrillar α-syn induce monocytes from healthy donors to express pro-IL-1β through TLR-2. However, only fibrillary α-syn increases release of mature IL-1β by activating the inflammasome [146].

α-syn expression in macrophages from healthy donors increases in response to LPS and IL-1β stimulation suggesting that α-syn has roles in inflammation and macrophage response [147]. Along these lines, macrophages from transgenic mice overexpressing α-syn have shown impaired phagocytosis, disrupted cytokine production, and defective debris clearance [44]. Whereas exogenous α-syn leads to murine macrophage activation and TNF-α production in a dose dependent manner. In this setting, the N terminus or NAC region may facilitate macrophage entry by α-syn, while the C terminus is necessary for cell activation [148]. Just as previously mentioned, SNARE protein complexes also mediate macrophage function. Cytokine release and phagocytosis are important functions of activated macrophages that are regulated by SNARE proteins [142]. Of note, SNARE protein expression is upregulated in LPS-activated macrophages [149, 150]. Among t-SNAREs in macrophages, syntaxin-4 and SNAP-23 are involved in secretion of TNF-α [149]; while VAMP3 is responsible for TNF-α exocytosis [150]. Syntaxin-4, SNAP-23 [149], and VAMP3 [150,151] also facilitate fusion of recycling endosome membranes to phagosomes to assist phagocytosis. In addition, VAMP7 is involved in fusion of late endosome membranes to phagosomes to complete phagosome maturation [152].

2.1.5. α-syn and MHC molecules

MHC molecules on PBMCs facilitate cell-cell interactions, and mediate cell maturation and differentiation. α-syn correlates with MHC expression in PBMCs and aberrant MHC expression has been reported in PD patients. Both increased number of MHC-II positive microglia [153], and increased MHC-I light-chain β2-microglobulin in the dopaminergic region of PD patients have been reported [154]. Furthermore, a gene variant in the noncoding single-nucleotide polymorphism region of the MHC-II locus alters its expression on B cells and monocytes in PD [155]. A recent study showed that α-syn is presented by specific MHC-I and MHC-II that activate cytotoxic and Th cells. Importantly, two antigenic regions in naïve and fibrillary α-syn, one near the C terminus and the other near the N terminus are presented in this manner [156].

2.1.6. α-syn in erythroid lineage

It has been reported that most of the α-syn in blood is found in erythrocytes since they are the most abundant cells; however, platelets have the highest concentration of α-syn per mg of cellular protein [157]. Of interest, α-syn$^{-/-}$ mice manifest mild anemia [68, 72]. In humans, α-syn is found in both erythroid precursors in the marrow and erythrocytes in peripheral blood, and changes in its expression may differentiate erythroid from megakaryocytic neoplasms [67]. The expression of α-syn in erythrocytes is regulated during cell differentiation, specifically during the terminal steps of erythrocyte development. Thus erythroblasts have higher α-syn expression than reticulocytes and erythrocytes [158]. Moreover, increased α-syn mRNA at the erythroblast stage and decreased at the enucleation stage have been described, while protein concentration steadily increases late in erythroblast differentiation [159]. In regard to α-syn conformations, tetrameric α-syn was first identified in RBCs and this conformation is aggregation resistant [19]; notably, monomeric and high molecular bands of α-syn are detected in the erythroid proliferative stage while only the monomeric form is detected in the erythroblast stage. Localization of α-syn also changes during erythrocyte differentiation so that it is found in the nucleus, the cytoplasm, and the plasma membrane [159, 160]. This regulated expression and localization of α-syn suggests that this protein is important in the erythroid lineage (Fig. 2).

Several functions of α-syn in erythrocytes have been proposed based on its biochemical properties and structure. Due to its capacity to interact with lipids, proteins and cell membranes, α-syn is thought of as a tether in erythrocytes [161]. In this model, the N-terminus of α-syn binds to the cell membrane while the free C-terminus binds to other proteins as a chaperone. This tethering function could allow cytosolic proteins to modulate those membrane-bound. Moreover, by binding to the inner leaflet of the plasma membrane, α-syn increases membrane mechanical strength thus regulating membrane fluidity, which might potentially extend erythrocyte lifespan [161]. Similarly, based on its different cellular localizations through RBC development α-syn may also be involved in erythroblast enucleation and stabilization of erythroid membrane [159].

α-syn may also be critical to maintaining iron homeostasis. Under normal conditions, iron is absorbed by intestinal enterocytes as ferrous, ferric, and heme iron, processed to ferric iron and bound to transferrin which then binds to the transferrin receptor 1 (TfR1) expressed on erythroblasts leading to its internalization by endocytosis [162]. Increased iron concentration in the brain has been described in PD suggesting disturbances in iron homeostasis [163]. Contrary to brain findings, serum iron, ferritin, and transferrin are decreased in PD patients [164]. Microarray studies have shown down-regulation of genes related to iron metabolism in PD patients. Gene analysis in PD indicated a connection between iron and hemoglobin (Hb) metabolism, and erythrocyte development with *SNCA* [165]. α-syn can also modulate trafficking of the transferrin/transferrin receptor (Tf/TfR) complex in erythrocytes, retina, and hematopoietic organs which utilize this pathway for iron uptake. This is demonstrated by α-syn$^{-/-}$ mice showing iron deficiency, decreased ferritin and TfR, leading to lower Hb synthesis in RBCs and spleen. In this model, α-syn facilitates both endocytosis and exocytosis of Tf/TfR complexes [166]. α-syn is also a ferric reductase capable of binding to Fe(III) and converting it to Fe(II), making it available to cellular functions [167]. Likewise, α-syn binds to Fe(II) with


Fig. 2. Diagram representing both erythrocyte (left half) and platelet/megakaryocyte (right half). Processes mediated or regulated by α-syn expression are shown. Similarly, conformation changes of the protein in RBCs indicated since this can mediate distinct functions.

a binding constant higher than that of transferrin binding to Fe(II) making α-syn a potential Fe(II) chaperone thus mediating iron transport [168]. In addition, α-syn regulates iron uptake and recycling by modulating phagocytes [162]. This may represent another potential pathway by which α-syn regulates iron homeostasis.

Beyond iron homeostasis regulation, α-syn interferes with both peripheral and neuronal Hb. It has been shown that both Hb and hematocrit positively correlate with serum α-syn concentration [169]. *SNCA* has also been linked to heme metabolism genes *ALAS2*, *FECH*, and *BLVRB* under GATA control, suggesting a role for α-syn in heme metabolism [170]. Microarray studies have indicated that down-regulation of genes related to Hb and erythrocyte-specific genes occur in PD patients [165]. α-syn-Hb complexes have also been identified in primates and humans. In the former, both RBC-derived α-syn-Hb complexes and neuro-striatal cytoplasmic-derived Hb-α-syn complexes show age-dependent increases [171]. On the other hand, in human RBCs, α-syn-Hb complexes concentration increases in acute ischemic stroke patients and is positively correlated with oligomerized and phosphorylated α-syn [172]. In summary, α-syn appears critical to the erythroid lineage through its regulation of iron and hemoglobin homeostasis.

2.1.7. α-syn in megakaryocytes and platelets

α-syn is well expressed in both megakaryocytes and platelets [173]. During megakaryocyte differentiation, α-syn is upregulated while β-syn is downregulated toward the end of megakaryocytic differentiation so that only α-syn is abundantly expressed in platelets suggesting that this protein plays an active role in the terminal differentiation of this lineage. External stimuli may also affect its expression in platelets since it changes with age and level of physical activity [174]. In platelets, α-syn is loosely associated with the plasma membrane, and membranes of organelles and secretory α-granules [173]; and it is found in platelet extracellular microvesicles [175]. Of interest, α-syn concentration increases in a time-dependent manner in plasma of single donor platelets during storage. This increase could result from platelets releasing their contents due to senescence or because of storage-dependent changes to platelets [31].

Abnormal platelet morphology characterized by larger size has been described in PD patients [176]; and platelet vacuoles, part of its open canalicular system important to aggregation, are also larger [177]. In contrast, studies in α-syn$^{-/-}$ mice have reported smaller platelets with extensive degranulation and fragmentation [72, 178]. Abnormal platelet function has also been shown in PD patients and α-syn$^{-/-}$ mice. In this regard, decreased platelet aggregation [179] and impaired platelet mitochondrial respiratory chain have been observed in PD patients [180]. Whilst higher CD62P expression in the absence of stimulation, as well as hypercoagulability has been shown in α-syn$^{-/-}$ mice [72, 178].

These changes in platelet morphology and function in the setting of altered α-syn expression suggest that this protein is essential to megakaryocytes and platelets (Fig. 2). It has been shown that one function of α-syn is as a calcium-dependent negative regulator of α-granule release from platelets [181]. Notably, exogenous α-syn penetrates platelets via its NAC domain and inhibits α-granule release via both its N- and C-termini [181]. This inhibitory function of α-syn has been reported in endothelial cells. Endogenously overexpressed and exogenous α-syn inhibit von Willebrand factor release and CD62P translocation in endothelial cells; and both N terminus and NAC region are needed for this inhibition [182]. Higher CD62P expression and degranulation of platelets in α-syn$^{-/-}$ mice lend support to this potential inhibitory role of α-syn [170].

Granule exocytosis, including vesicle docking, priming, triggering, and fusion is critical to platelet function. Several SNARE proteins are essential in these processes [183]. Syntaxins -2, -4, -7, and -11, and SNAP-23, -25, and -29 have been identified as t-SNARE proteins in platelets. VAMP8 is the critical v-SNARE for α-granule release, while VAMP2 and VAMP3 have subordinate roles [184]. However, without VAMP7 [185], there is partial dense granule and α-granule secretion deficit suggesting that this SNARE links exocytosis to cytoskeletal

reorganization during granule release. In the megakaryocyte-platelet lineage, endocytosis is as important as exocytosis. In megakaryocytes only part of the protein content of α-granules is synthesized by the cell and the remainder is actively endocytosed from blood. For example, fibrinogen in α-granules comes from plasma through endocytosis [186]. VAMP3 mediates endocytosis and membrane trafficking processes in platelets, which are important to fibrinogen uptake, platelet spreading, and clot retraction [187].

Alternatively, α-syn could interact with vesicular monoamine transporter 2 (VMAT2) to modulate platelet function. Under normal conditions, VMAT2 sequesters dopamine into synaptic vesicles for storage and release. Megakaryocytes express VMAT2 [188] and its mRNA is decreased in platelets of PD patients [189]. Along these lines, reduced expression of VMAT2 in mice leads to increased α-syn immunoreactivity and accumulation in SN [190].

The data presented suggests that α-syn is essential to megakaryocyte and platelet homeostasis and that SNARE protein modulation in both exocytosis and endocytosis are mechanistically important. Even though these underlying mechanisms remain to be elucidated, likely, lessons can be learned from what has been discovered in neurons since just as platelets neuronal granule release is paramount to normal cell function. Future research will determine these important functions mediated by α-syn in megakaryocytes and platelets.

2.1.8. α-synuclein and immunological diseases

The potential role of α-syn in diseases of the immune system is suggested by the available data, however, at the time of writing this manuscript no "syndrome/disease" has been associated to α-syn deficiency in the literature. Clearly, the preservation of this protein's sequence across species from rodents to humans indicates that this protein is important to maintain essential physiological/cellular responses. Studies using animal models have yielded information of the phenotype caused by α-syn deficiency. Defective development of mature T and B cells, regulatory T cells, disrupted cytokine profiles, lack of antibody class switching, abnormal lymphoid tissue morphology, abnormal leukocyte ultrastructure are all indicative that absence of this protein may lead to a substantial yet non-lethal phenotype. The latter is perhaps the reason for the lack of published literature due to residual immune function. However, as indicated earlier in this review there is growing literature indicating that mutations of the protein as those seen in some Parkinson's patients lead to abnormal T cell phenotypes, and therefore immune responses that could begin to shed light at potential immune sequelae caused by changes to this protein's sequence. As a result, additional research at potential disease mechanisms caused by these new findings is needed.

3. Conclusions

α-syn is a major pathological mediator in PD and is also ubiquitously expressed in the hematopoietic system under normal physiological conditions. Observations from PD patients and α-syn$^{-/-}$ mice point that this protein is critical to this system. Available data suggests that due to these potentially important functions its expression and conformation may be tightly regulated. α-syn may prove to be essential to exocytosis/endocytosis, apoptosis, autophagy, maturation, and differentiation of hematopoietic cells. In addition, alterations of α-syn occurring in the hematopoietic system could affect CNS cells either through extracellular vesicles or infiltrating immune cells. Undoubtedly, future research will contribute to a greater understanding of those physiologic pathways modulated by this protein.

Declarations

Author contribution statement

All authors listed have significantly contributed to the development

and the writing of this article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, M. Goedert, Alpha-synuclein in Lewy bodies, Nature 388 (1997) 839–840.

[2] A. Surguchov, Synucleins: are they two-edged swords? J. Neurosci. Res. 91 (2013) 161–166.

[3] S. Ltic, M. Perovic, A. Mladenovic, et al., Alpha-synuclein is expressed in different tissues during human fetal development, J. Mol. Neurosci. 22 (2004) 199–204.

[4] K. Ueda, T. Saitoh, H. Mori, Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid, Biochem. Biophys. Res. Commun. 205 (1994) 1366–1372.

[5] E.C. Shin, S.E. Cho, D.K. Lee, et al., Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages, Mol. Cells 10 (2000) 65–70.

[6] H. Zhang, R.W. Maitta, P.K. Bhattacharyya, et al., gamma-Synuclein is a promising new marker for staining reactive follicular dendritic cells, follicular dendritic cell sarcoma, Kaposi sarcoma, and benign and malignant vascular tumors, Am. J. Surg. Pathol. 35 (2011) 1857–1865.

[7] A. Abeliovich, Y. Schmitz, I. Farinas, et al., Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system, Neuron 25 (2000) 239–252.

[8] M. Hashimoto, E. Rockenstein, M. Mante, M. Mallory, E. Masliah, beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor, Neuron 32 (2001) 213–223.

[9] N.J. Rutherford, B.D. Moore, T.E. Golde, B.I. Giasson, Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein, J. Neurochem. 131 (2014) 859–867.

[10] S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion, et al., Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease, Mov. Disord. 28 (2013) 811–813.

[11] J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, et al., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia, Ann. Neurol. 55 (2004) 164–173.

[12] A.P. Kiely, Y.T. Asi, E. Kara, et al., alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125 (2013) 753–769.

[13] C.R. Bodner, A.S. Maltsev, C.M. Dobson, A. Bax, Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy, Biochemistry 49 (2010) 862–871.

[14] M.J. Benskey, R.G. Perez, F.P. Manfredsson, The contribution of alpha synuclein to neuronal survival and function - implications for Parkinson's disease, J. Neurochem. 137 (2016) 331–359.

[15] T.D. Kim, S.R. Paik, C.H. Yang, Structural and functional implications of C-terminal regions of alpha-synuclein, Biochemistry 41 (2002) 13782–13790.

[16] S. Kanda, J.F. Bishop, M.A. Eglitis, Y. Yang, M.M. Mouradian, Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation, Neuroscience 97 (2000) 279–284.

[17] M. Emanuele, E. Chieregatti, Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role, Biomolecules 5 (2015) 865–892.

[18] P.H. Weinreb, W. Zhen, A.W. Poon, K.A. Conway, P.T. Lansbury Jr., NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry 35 (1996) 13709–13715.

[19] T. Bartels, J.G. Choi, D.J. Selkoe, alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation, Nature 477 (2011) 107–110.

[20] W.S. Davidson, A. Jonas, D.F. Clayton, J.M. George, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes, J. Biol. Chem. 273 (1998) 9443–9449.

[21] E.R. Middleton, E. Rhoades, Effects of curvature and composition on alpha-synuclein binding to lipid vesicles, Biophys. J. 99 (2010) 2279–2288.

[22] M.M. Apetri, N.C. Maiti, M.G. Zagorski, P.R. Carey, V.E. Anderson, Secondary structure of alpha-synuclein oligomers: characterization by Raman and atomic force microscopy, J. Mol. Biol. 355 (2006) 63–71.

[23] B. Winner, R. Jappelli, S.K. Maji, et al., In vivo demonstration that alpha-synuclein oligomers are toxic, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 4194–4199.

[24] C. Kim, G. Lv, J.S. Lee, et al., Exposure to bacterial endotoxin generates a distinct strain of alpha-synuclein fibril, Sci. Rep. 6 (2016) 30891.

[25] S.C. Park, J.C. Moon, S.Y. Shin, et al., Functional characterization of alpha-synuclein protein with antimicrobial activity, Biochem. Biophys. Res. Commun. 478 (2016) 924–928.

[26] A.J. Schaser, V.R. Osterberg, S.E. Dent, et al., Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders, Sci. Rep. 9 (2019) 10919.

[27] R. Borghi, R. Marchese, A. Negro, et al., Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects, Neurosci. Lett. 287 (2000) 65–67.

[28] O.M. El-Agnaf, S.A. Salem, K.E. Paleologou, et al., Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma, FASEB J. 17 (2003) 1945–1947.

[29] P.H. Lee, G. Lee, H.J. Park, O.Y. Bang, I.S. Joo, K. Huh, The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy, J. Neural Transm. 113 (2006) 1435–1439.

[30] H.J. Lee, S. Patel, S.J. Lee, Intravesicular localization and exocytosis of alpha-synuclein and its aggregates, J. Neurosci. 25 (2005) 6016–6024.

[31] C.M. Stefaniuk, H. Hong, C.V. Harding, R.W. Maitta, alpha-synuclein concentration increases over time in plasma supernatant of single donor platelets, Eur. J. Haematol. 101 (2018) 630–634.

[32] M. Shi, C. Liu, T.J. Cook, et al., Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease, Acta Neuropathol. 128 (2014) 639–650.

[33] E. Emmanouilidou, K. Melachroinou, T. Roumeliotis, et al., Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival, J. Neurosci. 30 (2010) 6838–6851.

[34] J. Lamontagne-Proulx, I. St-Amour, R. Labib, et al., Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease, Neurobiol. Dis. 124 (2019) 163–175.

[35] J. Matsumoto, T. Stewart, L. Sheng, et al., Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease? Acta Neuropathol Commun 5 (2017) 71.

[36] Y. Xia, G. Zhang, C. Han, et al., Microglia as modulators of exosomal alpha-synuclein transmission, Cell Death Dis. 10 (2019) 174.

[37] S.J. Lee, Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease, J. Mol. Neurosci. 34 (2008) 17–22.

[38] Y.T. Sui, K.M. Bullock, M.A. Erickson, J. Zhang, W.A. Banks, Alpha synuclein is transported into and out of the brain by the blood-brain barrier, Peptides 62 (2014) 197–202.

[39] F.N. Emamzadeh, Alpha-synuclein structure, functions, and interactions, J. Res. Med. Sci. 21 (2016) 29.

[40] K. Saijo, C.K. Glass, Microglial cell origin and phenotypes in health and disease, Nat. Rev. Immunol. 11 (2011) 775–787.

[41] D. Boche, V.H. Perry, J.A. Nicoll, Review: activation patterns of microglia and their identification in the human brain, Neuropathol. Appl. Neurobiol. 39 (2013) 3–18.

[42] E. Croisier, L.B. Moran, D.T. Dexter, R.K. Pearce, M.B. Graeber, Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition, J. Neuroinflammation 2 (2005) 14.

[43] L. Rojanathammanee, E.J. Murphy, C.K. Combs, Expression of mutant alpha-synuclein modulates microglial phenotype in vitro, J. Neuroinflammation 8 (2011) 44.

[44] S.J. Gardai, W. Mao, B. Schule, et al., Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease, PLoS One 8 (2013), e71634.

[45] S. Theodore, S. Cao, P.J. McLean, D.G. Standaert, Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease, J. Neuropathol. Exp. Neurol. 67 (2008) 1149–1158.

[46] M.B. Watson, F. Richter, S.K. Lee, et al., Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein, Exp. Neurol. 237 (2012) 318–334.

[47] V. Sanchez-Guajardo, F. Febbraro, D. Kirik, M. Romero-Ramos, Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease, PLoS One 5 (2010), e8784.

[48] S.A. Austin, A.M. Floden, E.J. Murphy, C.K. Combs, Alpha-synuclein expression modulates microglial activation phenotype, J. Neurosci. 26 (2006) 10558–10563.

[49] S.A. Austin, L. Rojanathammanee, M.Y. Golovko, E.J. Murphy, C.K. Combs, Lack of alpha-synuclein modulates microglial phenotype in vitro, Neurochem. Res. 36 (2011) 994–1004.

[50] M.L. Block, L. Zecca, J.-S. Hong, Microglia-mediated neurotoxicity: uncovering the molecular mechanisms, Nat. Rev. Neurosci. 8 (2007) 57.

[51] A. ElAli, S. Rivest, Microglia ontology and signaling, Front Cell Dev Biol 4 (2016) 72.

[52] C. Kim, E.D. Cho, H.K. Kim, et al., beta1-integrin-dependent migration of microglia in response to neuron-released alpha-synuclein, Exp. Mol. Med. 46 (2014) e91.

[53] C. Kim, D.-H. Ho, J.-E. Suk, et al., Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia, Nat. Commun. 4 (2013) 1562.

[54] C.D. Hughes, M.L. Choi, M. Ryten, et al., Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson's disease pathogenesis, Acta Neuropathol. 137 (2019) 103–120.

[55] D. Beraud, M. Twomey, B. Bloom, et al., Alpha-synuclein alters toll-like receptor expression, Front. Neurosci. 5 (2011) 80.

[56] X. Su, K.A. Maguire-Zeiss, R. Giuliano, L. Prifti, K. Venkatesh, H.J. Federoff, Synuclein activates microglia in a model of Parkinson's disease, Neurobiol. Aging 29 (2008) 1690–1701.

[57] N. Panicker, S. Sarkar, D.S. Harischandra, et al., Fyn kinase regulates misfolded alpha-synuclein uptake and NLRP3 inflammasome activation in microglia, J. Exp. Med. 216 (2019) 1411–1430.

[58] X. Su, H.J. Federoff, K.A. Maguire-Zeiss, Mutant alpha-synuclein overexpression mediates early proinflammatory activity, Neurotox. Res. 16 (2009) 238–254.

[59] W. Zhang, S. Dallas, D. Zhang, et al., Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein, Glia 55 (2007) 1178–1188.

[60] S. Wang, C.H. Chu, T. Stewart, et al., alpha-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) E1926–E1935.

[61] S. Cao, D.G. Standaert, A.S. Harms, The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia, J. Neuroinflammation 9 (2012) 259.

[62] S. Cao, S. Theodore, D.G. Standaert, Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease, Mol. Neurodegener. 5 (2010) 42.

[63] J. Haslund-Vinding, G. McBean, V. Jaquet, F. Vilhardt, NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease, Br. J. Pharmacol. 174 (2017) 1733–1749.

[64] W. Zhang, T. Wang, Z. Pei, et al., Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease, FASEB J. 19 (2005) 533–542.

[65] A.S. Harms, S. Cao, A.L. Rowse, et al., MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration, J. Neurosci. 33 (2013) 9592–9600.

[66] A. Sommer, T. Fadler, E. Dorfmeister, et al., Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model, J. Neuroinflammation 13 (2016) 174.

[67] R.W. Maitta, L.R. Wolgast, Q. Wang, et al., Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia, Am. J. Hematol. 86 (2011) 230–234.

[68] W. Xiao, A. Shameli, C.V. Harding, H.J. Meyerson, R.W. Maitta, Late stages of hematopoiesis and B cell lymphopoiesis are regulated by alpha-synuclein, a key player in Parkinson's disease, Immunobiology 219 (2014) 836–844.

[69] A. Shameli, W. Xiao, Y. Zheng, et al., A critical role for alpha-synuclein in development and function of T lymphocytes, Immunobiology 221 (2016) 333–340.

[70] H. Tashkandi, A. Shameli, C.V. Harding, R.W. Maitta, Ultrastructural changes in peripheral blood leukocytes in alpha-synuclein knockout mice, Blood Cells Mol. Dis. 73 (2018) 33–37.

[71] R. Savica, B.R. Grossardt, J.M. Carlin, et al., Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study, Neurology 73 (2009) 1381–1387.

[72] H. Tashkandi, A. Shameli, C.V. Harding, R.W. Maitta, Ultrastructural changes in peripheral blood leukocytes in α-synuclein knockout mice, Blood Cells Mol. Dis. 73 (2018) 33–37.

[73] S. Kim, B.S. Jeon, C. Heo, et al., Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease, FASEB J. 18 (2004) 1615–1617.

[74] Y.Y. Tan, L. Wu, Z.B. Zhao, et al., Methylation of alpha-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients, Park. Relat. Disord. 20 (2014) 308–313.

[75] H. Qin, J.A. Buckley, X. Li, et al., Inhibition of the JAK/STAT pathway protects against alpha-synuclein-induced neuroinflammation and dopaminergic neurodegeneration, J. Neurosci. 36 (2016) 5144–5159.

[76] S.F. Ziegler, FOXP3: not just for regulatory T cells anymore, Eur. J. Immunol. 37 (2007) 21–23.

[77] L.E. Harrington, R.D. Hatton, P.R. Mangan, et al., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages, Nat. Immunol. 6 (2005) 1123–1132.

[78] N.P. Rocha, F. Assis, P.L. Scalzo, et al., Reduced activated T lymphocytes (CD4+CD25+) and plasma levels of cytokines in Parkinson's disease, Mol. Neurobiol. 55 (2018) 1488–1497.

[79] Y. Baba, A. Kuroiwa, R.J. Uitti, Z.K. Wszolek, T. Yamada, Alterations of T-lymphocyte populations in Parkinson disease, Park. Relat. Disord. 11 (2005) 493–498.

[80] M. Calopa, J. Bas, A. Callen, M. Mestre, Apoptosis of peripheral blood lymphocytes in Parkinson patients, Neurobiol. Dis. 38 (2010) 1–7.

[81] Y. Chen, B. Qi, W. Xu, et al., Clinical correlation of peripheral CD4+cell subsets, their imbalance and Parkinson's disease, Mol. Med. Rep. 12 (2015) 6105–6111.

[82] C.H. Stevens, D. Rowe, M.C. Morel-Kopp, et al., Reduced T helper and B lymphocytes in Parkinson's disease, J. Neuroimmunol. 252 (2012) 95–99.

[83] J.A. Saunders, K.A. Estes, L.M. Kosloski, et al., CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease, J. Neuroimmune Pharmacol. 7 (2012) 927–938.

[84] F. Niwa, N. Kuriyama, M. Nakagawa, J. Imanishi, Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease, Geriatr. Gerontol. Int. 12 (2012) 102–107.

[85] J. Bas, M. Calopa, M. Mestre, et al., Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism, J. Neuroimmunol. 113 (2001) 146–152.

[86] B. Ettle, K. Kuhbandner, S. Jorg, A. Hoffmann, J. Winkler, R.A. Linker, alpha-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses, J. Neuroinflammation 13 (2016) 201.

[87] V. Sanchez-Guajardo, A. Annibali, P.H. Jensen, M. Romero-Ramos, alpha-Synuclein vaccination prevents the accumulation of Parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model, J. Neuropathol. Exp. Neurol. 72 (2013) 624–645.

[88] A. Labrador-Garrido, M. Cejudo-Guillen, R. Klippstein, et al., Chaperoned amyloid proteins for immune manipulation: alpha-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype, Immun Inflamm Dis 2 (2014) 226–238.

[89] A.D. Reynolds, D.K. Stone, J.A. Hutter, E.J. Benner, R.L. Mosley, H.E. Gendelman, Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease, J. Immunol. 184 (2010) 2261–2271.

[90] M.N. Olesen, J.R. Christiansen, S.V. Petersen, et al., CD4 T cells react to local increase of alpha-synuclein in a pathology-associated variant-dependent manner and modify brain microglia in absence of brain pathology, Heliyon 4 (2018), e00513.

[91] W. Hong, SNAREs and traffic, Biochim. Biophys. Acta 1744 (2005) 120–144.

[92] R. Jahn, R.H. Scheller, SNAREs–engines for membrane fusion, Nat. Rev. Mol. Cell Biol. 7 (2006) 631–643.

[93] R. Jahn, T.C. Sudhof, Membrane fusion and exocytosis, Annu. Rev. Biochem. 68 (1999) 863–911.

[94] T.C. Sudhof, The presynaptic active zone, Neuron 75 (2012) 11–25.

[95] S. Chandra, G. Gallardo, R. Fernandez-Chacon, O.M. Schluter, T.C. Sudhof, Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration, Cell 123 (2005) 383–396.

[96] J. Diao, J. Burre, S. Vivona, et al., Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2, Elife 2 (2013), e00592.

[97] J. Burre, M. Sharma, T.C. Sudhof, alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) E4274–E4283.

[98] J. Burre, M. Sharma, T. Tsetsenis, V. Buchman, M.R. Etherton, T.C. Sudhof, Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro, Science 329 (2010) 1663–1667.

[99] F. Darios, V. Ruiperez, I. Lopez, J. Villanueva, L.M. Gutierrez, B. Davletov, Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis, EMBO Rep. 11 (2010) 528–533.

[100] Y. Lai, S. Kim, J. Varkey, et al., Nonaggregated alpha-synuclein influences SNARE-dependent vesicle docking via membrane binding, Biochemistry 53 (2014) 3889–3896.

[101] B.K. Choi, M.G. Choi, J.Y. Kim, et al., Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 4087–4092.

[102] J.L. Stow, A.P. Manderson, R.Z. Murray, SNAREing immunity: the role of SNAREs in the immune system, Nat. Rev. Immunol. 6 (2006) 919–929.

[103] B. Alarcon, D. Mestre, N. Martinez-Martin, The immunological synapse: a cause or consequence of T-cell receptor triggering? Immunology 133 (2011) 420–425.

[104] G. de Saint Basile, G. Menasche, A. Fischer, Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules, Nat. Rev. Immunol. 10 (2010) 568–579.

[105] L. Klein, B. Kyewski, P.M. Allen, K.A. Hogquist, Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see), Nat. Rev. Immunol. 14 (2014) 377–391.

[106] N. Kanwar, A. Fayyazi, B. Backofen, M. Nitsche, R. Dressel, G.F. von Mollard, Thymic alterations in mice deficient for the SNARE protein VAMP8/endobrevin, Cell Tissue Res. 334 (2008) 227–242.

[107] P.A. Roche, K. Furuta, The ins and outs of MHC class II-mediated antigen processing and presentation, Nat. Rev. Immunol. 15 (2015) 203–216.

[108] J. Lou, J. Rossy, Q. Deng, S.V. Pageon, K. Gaus, New insights into how trafficking regulates T cell receptor signaling, Front Cell Dev Biol 4 (2016) 77.

[109] V. Das, B. Nal, A. Dujeancourt, et al., Activation-induced polarized recycling targets T cell antigen receptors to the immunological synapse; involvement of SNARE complexes, Immunity 20 (2004) 577–588.

[110] V. Pattu, B. Qu, M. Marshall, et al., Syntaxin7 is required for lytic granule release from cytotoxic T lymphocytes, Traffic 12 (2011) 890–901.

[111] H. Soares, R. Henriques, M. Sachse, et al., Regulated vesicle fusion generates signaling nanoterritories that control T cell activation at the immunological synapse, J. Exp. Med. 210 (2013) 2415–2433.

[112] M. Huse, B.F. Lillemeier, M.S. Kuhns, D.S. Chen, M.M. Davis, T cells use two directionally distinct pathways for cytokine secretion, Nat. Immunol. 7 (2006) 247–255.

[113] M. Barry, R.C. Bleackley, Cytotoxic T lymphocytes: all roads lead to death, Nat. Rev. Immunol. 2 (2002) 401–409.

[114] U. Matti, V. Pattu, M. Halimani, et al., Synaptobrevin2 is the v-SNARE required for cytotoxic T-lymphocyte lytic granule fusion, Nat. Commun. 4 (2013) 1439.

[115] L.S. Loo, L.A. Hwang, Y.M. Ong, H.S. Tay, C.C. Wang, W. Hong, A role for endobrevin/VAMP8 in CTL lytic granule exocytosis, Eur. J. Immunol. 39 (2009) 3520–3528.

[116] W. Hong, Cytotoxic T lymphocyte exocytosis: bring on the SNAREs!, Trends Cell Biol. 15 (2005) 644–650.

[117] P. Chitirala, K. Ravichandran, D. Galgano, et al., Cytotoxic granule exocytosis from human cytotoxic T lymphocytes is mediated by VAMP7, Front. Immunol. 10 (2019) 1855.

[118] M.E. Peter, P.H. Krammer, Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis, Curr. Opin. Immunol. 10 (1998) 545–551.

[119] N. Mizushima, B. Levine, A.M. Cuervo, D.J. Klionsky, Autophagy fights disease through cellular self-digestion, Nature 451 (2008) 1069–1075.

[120] A. Prigione, F. Piazza, L. Brighina, et al., Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease, Neurosci. Lett. 477 (2010) 6–10.

[121] T. Colasanti, M. Vomero, C. Alessandri, et al., Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes, Cell Death Dis. 5 (2014) e1265.

[122] Y. Miki, S. Shimoyama, T. Kon, et al., Alteration of autophagy-related proteins in peripheral blood mononuclear cells of patients with Parkinson's disease, Neurobiol. Aging 63 (2018) 33–43.

[123] N. Kustrimovic, E. Rasini, M. Legnaro, F. Marino, M. Cosentino, Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease, J. Neuroimmune Pharmacol. 9 (2014) 302–312.

[124] K. Nakano, T. Higashi, R. Takagi, K. Hashimoto, Y. Tanaka, S. Matsushita, Dopamine released by dendritic cells polarizes Th2 differentiation, Int. Immunol. 21 (2009) 645–654.

[125] H. Gonzalez, F. Contreras, C. Prado, et al., Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease, J. Immunol. 190 (2013) 5048–5056.

[126] M.J. Besser, Y. Ganor, M. Levite, Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both, J. Neuroimmunol. 169 (2005) 161–171.

[127] N. Kustrimovic, E. Rasini, M. Legnaro, et al., Dopaminergic receptors on CD4+ T naive and memory lymphocytes correlate with motor impairment in patients with Parkinson's disease, Sci. Rep. 6 (2016) 33738.

[128] J.R. Christiansen, M.N. Olesen, D.E. Otzen, M. Romero-Ramos, V. Sanchez-Guajardo, alpha-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology, J. Neuroinflammation 13 (2016) 74.

[129] N.A. Mitchison, T-cell-B-cell cooperation, Nat. Rev. Immunol. 4 (2004) 308–312.

[130] C.F. Orr, D.B. Rowe, Y. Mizuno, H. Mori, G.M. Halliday, A possible role for humoral immunity in the pathogenesis of Parkinson's disease, Brain 128 (2005) 2665–2674.

[131] K.K. Papachroni, N. Ninkina, A. Papapanagiotou, et al., Autoantibodies to alpha-synuclein in inherited Parkinson's disease, J. Neurochem. 101 (2007) 749–756.

[132] E. Masliah, E. Rockenstein, A. Adame, et al., Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease, Neuron 46 (2005) 857–868.

[133] L. Gomez-Jaramillo, R. Romero-Garcia, G. Jimenez-Gomez, et al., VAMP2 is implicated in the secretion of antibodies by human plasma cells and can be replaced by other synaptobrevins, Cell. Mol. Immunol. 15 (2018) 353–366.

[134] E. Reales, F. Mora-Lopez, V. Rivas, A. Garcia-Poley, J.A. Brieva, A. Campos-Caro, Identification of soluble N-ethylmaleimide-sensitive factor attachment protein receptor exocytotic machinery in human plasma cells: SNAP-23 is essential for antibody secretion, J. Immunol. 175 (2005) 6686–6693.

[135] L. Gomez-Jaramillo, L. Delgado-Perez, E. Reales, et al., Syntaxin-4 is implicated in the secretion of antibodies by human plasma cells, J. Leukoc. Biol. 95 (2014) 305–312.

[136] W. Hoffman, F.G. Lakkis, G. Chalasani, B cells, antibodies, and more, Clin. J. Am. Soc. Nephrol. 11 (2016) 137–154.

[137] F. McKenna, P.J. McLaughlin, B.J. Lewis, et al., Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study, J. Neuroimmunol. 132 (2002) 34–40.

[138] J.S. Orange, Z.K. Ballas, Natural killer cells in human health and disease, Clin. Immunol. 118 (2006) 1–10.

[139] E. Caggiu, K. Paulus, G. Galleri, et al., Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease, J. Neuroimmunol. 310 (2017) 26–31.

[140] K. Krzewski, A. Gil-Krzewska, J. Watts, J.N. Stern, J.L. Strominger, VAMP4- and VAMP7-expressing vesicles are both required for cytotoxic granule exocytosis in NK cells, Eur. J. Immunol. 41 (2011) 3323–3329.

[141] A. Dabrazhynetskaya, J. Ma, A.O. Guerreiro-Cacais, et al., Syntaxin 11 marks a distinct intracellular compartment recruited to the immunological synapse of NK cells to colocalize with cytotoxic granules, J. Cell Mol. Med. 16 (2012) 129–141.

[142] J. Yang, L. Zhang, C. Yu, X.F. Yang, H. Wang, Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases, Biomark Res 2 (2014) 1.

[143] V. Grozdanov, C. Bliederhaeuser, W.P. Ruf, et al., Inflammatory dysregulation of blood monocytes in Parkinson's disease patients, Acta Neuropathol. 128 (2014) 651–663.

[144] A.S. Harms, A.D. Thome, Z. Yan, et al., Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease, Exp. Neurol. 300 (2018) 179–187.

[145] A. Klegeris, S. Pelech, B.I. Giasson, et al., Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia, Neurobiol. Aging 29 (2008) 739–752.

[146] G. Codolo, N. Plotegher, T. Pozzobon, et al., Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies, PLoS One 8 (2013), e55375.

[147] K. Tanji, F. Mori, T. Imaizumi, et al., Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages, Pathol. Int. 52 (2002) 572–577.

[148] S.B. Lee, S.M. Park, K.J. Ahn, K.C. Chung, S.R. Paik, J. Kim, Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation, Biochem. Biophys. Res. Commun. 381 (2009) 39–43.

[149] J.K. Pagan, F.G. Wylie, S. Joseph, et al., The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion, Curr. Biol. 13 (2003) 156–160.

[150] R.Z. Murray, J.G. Kay, D.G. Sangermani, J.L. Stow, A role for the phagosome in cytokine secretion, Science 310 (2005) 1492–1495.

[151] L. Bajno, X.R. Peng, A.D. Schreiber, H.P. Moore, W.S. Trimble, S. Grinstein, Focal exocytosis of VAMP3-containing vesicles at sites of phagosome formation, J. Cell Biol. 149 (2000) 697–706.

[152] V. Braun, V. Fraisier, G. Raposo, et al., TI-VAMP/VAMP7 is required for optimal phagocytosis of opsonised particles in macrophages, EMBO J. 23 (2004) 4166–4176.

[153] P.L. McGeer, S. Itagaki, B.E. Boyes, E.G. McGeer, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology 38 (1988) 1285–1291.

[154] M. Mogi, M. Harada, T. Kondo, P. Riederer, T. Nagatsu, Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease, J Neural Transm Park Dis Dement Sect 9 (1995) 87–92.

[155] T.H. Hamza, C.P. Zabetian, A. Tenesa, et al., Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease, Nat. Genet. 42 (2010) 781–785.

[156] D. Sulzer, R.N. Alcalay, F. Garretti, et al., T cells from patients with Parkinson's disease recognize alpha-synuclein peptides, Nature 546 (2017) 656–661.

[157] R. Barbour, K. Kling, J.P. Anderson, et al., Red blood cells are the major source of alpha-synuclein in blood, Neurodegener. Dis. 5 (2008) 55–59.

[158] M. Nakai, M. Fujita, M. Waragai, et al., Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage, Biochem. Biophys. Res. Commun. 358 (2007) 104–110.

[159] K. Araki, K. Sugawara, E.H. Hayakawa, et al., The localization of alpha-synuclein in the process of differentiation of human erythroid cells, Int. J. Hematol. 108 (2018) 130–138.

[160] G. Liu, C. Tian, L. Gao, Z. Cao, T. Feng, Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: a pilot study, Park. Relat. Disord. 60 (2019) 105–110.

[161] S.N. Witt, Molecular chaperones, alpha-synuclein, and neurodegeneration, Mol. Neurobiol. 47 (2013) 552–560.

[162] A.A. Belaidi, A.I. Bush, Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics, J. Neurochem. 139 (Suppl 1) (2016) 179–197.

[163] E. Sofic, P. Riederer, H. Heinsen, et al., Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain, J. Neural Transm. 74 (1988) 199–205.

[164] G. Logroscino, K. Marder, J. Graziano, et al., Altered systemic iron metabolism in Parkinson's disease, Neurology 49 (1997) 714–717.

[165] J.A. Santiago, J.A. Potashkin, Blood transcriptomic meta-analysis identifies dysregulation of hemoglobin and iron metabolism in Parkinson' disease, Front. Aging Neurosci. 9 (2017) 73.

[166] S. Baksi, A.K. Tripathi, N. Singh, Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: implications for visual manifestations of Parkinson's disease, Free Radic. Biol. Med. 97 (2016) 292–306.

[167] P. Davies, D. Moualla, D.R. Brown, Alpha-synuclein is a cellular ferrireductase, PLoS One 6 (2011), e15814.

[168] Y. Peng, C. Wang, H.H. Xu, Y.N. Liu, F. Zhou, Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes, J. Inorg. Biochem. 104 (2010) 365–370.

[169] G. Rodriguez-Araujo, H. Nakagami, Y. Takami, et al., Low alpha-synuclein levels in the blood are associated with insulin resistance, Sci. Rep. 5 (2015) 12081.

[170] C.R. Scherzer, J.A. Grass, Z. Liao, et al., GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10907–10912.

[171] W. Yang, X. Li, X. Li, X. Li, S. Yu, Neuronal hemoglobin in mitochondria is reduced by forming a complex with alpha-synuclein in aging monkey brains, Oncotarget 7 (2016) 7441–7454.

[172] Z. Wu, X. Li, M. Zeng, et al., Alpha-synuclein alterations in red blood cells of peripheral blood after acute ischemic stroke, Int. J. Clin. Exp. Pathol. 12 (2019) 1757–1763.

[173] M. Hashimoto, M. Yoshimoto, A. Sisk, et al., NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation, Biochem. Biophys. Res. Commun. 237 (1997) 611–616.

[174] S. Daniele, D. Pietrobono, J. Fusi, et al., Alpha-synuclein aggregates with beta-amyloid or tau in human red blood cells: correlation with antioxidant capability and physical exercise in human healthy subjects, Mol. Neurobiol. 55 (2018) 2653–2675.

[175] A. Pienimaeki-Roemer, K. Kuhlmann, A. Bottcher, et al., Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets, Transfusion 55 (2015) 507–521.

[176] A. Kocer, A. Yaman, E. Niftaliyev, H. Duruyen, M. Eryilmaz, E. Kocer, Assessment of platelet indices in patients with neurodegenerative diseases: mean platelet volume was increased in patients with Parkinson's disease, Curr Gerontol Geriatr Res 2013 (2013) 986254.

[177] S.A. Factor, E. Ortof, M.P. Dentinger, R. Mankes, K.D. Barron, Platelet morphology in Parkinson's disease: an electron microscopic study, J. Neurol. Sci. 122 (1994) 84–89.

[178] H. Tashkandi, A. Shameli, R.W. Maitta, Dysregulation of platelet function and morphology in the setting of alpha-synuclein deficiency, Transfusion 56 (4S) (2016) 117A.

[179] P. Sharma, D. Nag, V. Atam, P.K. Seth, V.K. Khanna, Platelet aggregation in patients with Parkinson's disease, Stroke 22 (1991) 1607–1608.

[180] R.H. Haas, F. Nasirian, K. Nakano, et al., Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease, Ann. Neurol. 37 (1995) 714–722.

[181] S.M. Park, H.Y. Jung, H.O. Kim, et al., Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets, Blood 100 (2002) 2506–2514.

[182] K.S. Kim, J.Y. Park, I. Jou, S.M. Park, Regulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells, J. Biol. Chem. 285 (2010) 21416–21425.

[183] G.L. Reed, M.L. Fitzgerald, J. Polgar, Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes, Blood 96 (2000) 3334–3342.

[184] P. Blair, R. Flaumenhaft, Platelet alpha-granules: basic biology and clinical correlates, Blood Rev. 23 (2009) 177–189.

[185] S. Koseoglu, C.G. Peters, J.L. Fitch-Tewfik, et al., VAMP-7 links granule exocytosis to actin reorganization during platelet activation, Blood 126 (2015) 651–660.

[186] P. Harrison, B. Wilbourn, N. Debili, et al., Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets, J Clin Invest 84 (1989) 1320–1324.

[187] M. Banerjee, S. Joshi, J. Zhang, et al., Cellubrevin/vesicle-associated membrane protein-3-mediated endocytosis and trafficking regulate platelet functions, Blood 130 (2017) 2872–2883.

[188] M. Anlauf, M.K. Schafer, T. Schwark, et al., Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis, J. Histochem. Cytochem. 54 (2006) 201–213.

[189] G. Sala, L. Brighina, E. Saracchi, et al., Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease, J. Neural Transm. 117 (2010) 1093–1098.

[190] W.M. Caudle, J.R. Richardson, M.Z. Wang, et al., Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration, J. Neurosci. 27 (2007) 8138–8148.